Raina Biosciences Inc., a Boston-based MIT spinout, has developed GEMORNA, a groundbreaking generative AI platform designed specifically for mRNA sequence creation and optimization.

GEMORNA produces superior linear and circular mRNA molecules with enhanced expression, stability, and durability, addressing key limitations of existing mRNA therapeutics.

As the world's first purpose-built AI platform for mRNA design, GEMORNA can generate optimized sequences directly from a vast design space, accelerating drug discovery and reducing the need for iterative testing.

GEMORNA-generated mRNAs have demonstrated significantly improved performance, including up to a 150-fold increase in therapeutic protein expression, higher immune responses in mice, and enhanced CAR T cell efficacy.

The platform has also improved CAR T cell therapies, achieving a fivefold increase in CD19 CAR expression and nearly 100% anti-tumor efficacy in human T cells.

These advancements support applications in mRNA-based vaccines for diseases like cancer, with the platform boosting immune responses compared to existing vaccines.

The technology's ability to significantly increase protein expression highlights its potential for gene therapy and other therapeutic areas.

Raina aims to revolutionize mRNA drug development by overcoming current limitations and expanding therapeutic possibilities through AI-driven sequence design.

Founded as a spinout from MIT and based in Boston, Raina has secured early-stage funding, collaborates with leading pharma and biotech companies, and seeks to accelerate mRNA therapeutics beyond infectious diseases.

The company’s leadership includes experienced scientists and entrepreneurs, supported by a $5.7 million angel investment, positioning Raina at the forefront of RNA therapeutics innovation.

Industry experts and leaders believe GEMORNA could transform the development of mRNA therapies for cancer, gene editing, and other fields by enabling rapid, precise, and reliable sequence design.